This is a prospective, multi-center, observational and cohort study for patients with IBD. This study will assess the effectiveness of vedolizumab for achieving clinical response at Week 12 and remission at Week 52 in participants with confirmed and active disease of ulcerative colitis (UC) and Crohn’s disease (CD), and will assess the long term effectiveness of vedolizumab treatment among 3 months responders or remitters in clinical practice.
Trial at a glance
What medical condition is being studied? Inflammatory Bowel Disease
How many participants are being enrolled? 300
When is the trial being conducted?
From 18 Years
Accepts Healthy Volunteers?
Trial Details / Participation Requirements
CLICK TO EXPANDCLICK TO COLLAPSE
Trial Type: Observational